{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+10+mg&page=2",
    "query": {
      "intervention": "Dapagliflozin 10 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 187,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+10+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+10+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T01:47:09.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03877237",
      "title": "DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction (HFrEF)"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "150 Years",
        "sex": "ALL",
        "summary": "18 Years to 150 Years"
      },
      "enrollment_count": 313,
      "start_date": "2019-04-09",
      "completion_date": "2020-03-07",
      "has_results": true,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 23,
      "location_summary": "Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03877237"
    },
    {
      "nct_id": "NCT02981966",
      "title": "Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2019-05-23",
      "completion_date": "2023-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981966"
    },
    {
      "nct_id": "NCT02681094",
      "title": "A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Inadequate Glycaemic Control"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Saxagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 905,
      "start_date": "2016-02-26",
      "completion_date": "2017-07-15",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 48,
      "location_summary": "Saraland, Alabama • Fresno, California • Harbor City, California + 41 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        },
        {
          "city": "Hawaiian Gardens",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02681094"
    },
    {
      "nct_id": "NCT00930865",
      "title": "Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bumetanide",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 42,
      "start_date": "2009-07",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2016-10-17",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00930865"
    },
    {
      "nct_id": "NCT05025735",
      "title": "Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10Mg Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint Luke's Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-25",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025735"
    },
    {
      "nct_id": "NCT01525238",
      "title": "PK Study of Dapagliflozin in Pediatric Subjects With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 53,
      "start_date": "2012-07-01",
      "completion_date": "2014-09-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525238"
    },
    {
      "nct_id": "NCT06350123",
      "title": "Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-05-01",
      "completion_date": "2025-05-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 15,
      "location_summary": "Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06350123"
    },
    {
      "nct_id": "NCT02695082",
      "title": "Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 539310,
      "start_date": "2017-01-01",
      "completion_date": "2020-11-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-07",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 2,
      "location_summary": "Wilmington, Delaware • Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02695082"
    },
    {
      "nct_id": "NCT05741658",
      "title": "The Fontan Dapagliflozin Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10mg Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2023-11-08",
      "completion_date": "2026-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05741658"
    },
    {
      "nct_id": "NCT00688493",
      "title": "Effects of Single Oral Dose Dapagliflozin QT Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match moxifloxacin and dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2007-07",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2012-03-21",
      "last_synced_at": "2026-10-09T01:47:09.855Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688493"
    }
  ]
}